This conclusion can aid better personalized medicine for lung cancer management, while further assessment for genetic variants of <i>CYP3A4</i>, <i>CYP27B1</i>, <i>CYP24A1</i>, <i>GC</i>, and <i>VDR</i> is still required to address more robust evidence. This evidence concerns the gene CYP3A4 and lung cancer.